Physician profile
Maria E Gallegos
NPI 1306206305
$1,051.75
in general payments reported to CMS, 2019-2025
21 companies · $632 in 2025
The $632 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.25 · 2022: $40.11 · 2023: $69.72 · 2024: $276 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $179.77 | 2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $120.92 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $101.29 | 2025 | Spravato |
| Lilly USA, LLC | $99.68 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $95.35 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $66.79 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $55.56 | 2024-2025 | Eliquis, Camzyos |
| Aimmune Therapeutics, INC. | $37.16 | 2025 | Vowst |
| Bayer Healthcare Pharmaceuticals INC. | $33.68 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.76 | 2024-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $27.44 | 2023 | Livalo, Seglentis |
| Medline Industries LP | $26.72 | 2025 | |
| Dexcom, INC. | $24.70 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $24.17 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $22.48 | 2024 | Gattex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.44 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.63 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $19.26 | 2024 | Voquezna |
| Amgen INC. | $15.95 | 2025 | Evenity |
| Glaxosmithkline, LLC. | $14.46 | 2023 | Arexvy, Shingrix |
| Nestle Healthcare Nutrition INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Gallegos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.